Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chemotherapy Induced Peripheral Neuropathy
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Chemotherapy can cause a variety of side effects. One of the most common side effects is Chemotherapy induced peripheral neuropathy (CIPN), it commonly caused by Paclitaxel chemotherapy which is usually used in the treatment of breast cancer. Metformin which is known as a safe anti-diabetic drug, wa...
Chemotherapy can cause a variety of side effects. One of the most common side effects is Chemotherapy induced peripheral neuropathy (CIPN), it commonly caused by Paclitaxel chemotherapy which is usually used in the treatment of breast cancer. Metformin which is known as a safe anti-diabetic drug, was found to have a protective effect on neurons. It gave positive results in chemotherapy induced peripheral neuropathy in mouse models and in some clinical trials
Tracking Information
- NCT #
- NCT04780854
- Collaborators
- German University in Cairo
- Investigators
- Study Chair: Mohamed H. Solayman, PhD. Pharm. German University in Cairo Principal Investigator: Loay M. Kassem, PhD Cairo University Principal Investigator: Danira Ashraf Habashy, PhD Pharm. German University in Cairo Principal Investigator: Sara A. Mosa, Bsc German University in Cairo
Get Well Soon